Currently, ICIs are approved for several indications across various cancers.297 In advanced NSCLC, ICIs are usually the standard of care (alone or in combination with chemotherapy) in patients who lack driver mutations.298 This population includes patients with KRAS mutations, for whom sotorasib and adagrasib are approved only as second-line agents and who are likely to receive ICIs. This evidence concerns the gene KRAS and non-small cell lung carcinoma.